Argent Trust Co’s Moderna MRNA Stock Holding History

Argent Trust Co’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,044	Closed	-$218K	–	722
2024 Q1	$218K	Buy	+2,044	New	+$206K	0.01%	633
2023 Q3	–	Sell	-1,760	Closed	-$214K	–	678
2023 Q2	$214K	Buy	+1,760	New	+$235K	0.01%	580

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Argent Trust Co's MRNA Position: Q2 2024 in Review

Argent Trust Co sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,044 shares — an estimated $218K sold.

Argent Trust Co first reported a position in MRNA in Q2 2023 and held it in 2 quarters. The position peaked at $218K in Q1 2024. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Argent Trust Co reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Argent Trust Co sold 2,044 Moderna shares in Q2 2024, an estimated $218K.
Argent Trust Co first reported a position in Moderna in Q2 2023 and held it in 2 quarters.
Argent Trust Co's Moderna position peaked at $218K in Q1 2024.
954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Argent Trust Co's 13F filing for Q2 2024, filed 12 Aug 2024.